Jazz Pharmaceuticals Financials - Benzinga

Jazz Pharmaceuticals PLC

JAZZNASDAQ

Trade with Public

Trade with Public

$238.28

0.330.14%

近くで: Sep 28, 5:00 PM EST

$238.20

-0.08-0.03%

時間外: 4:24 PM EST

概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Jazz Pharmaceuticals Financials

Jazz Pharmaceuticals (JAZZ) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

These Analysts Increase Their Forecasts On Jazz Pharmaceuticals Following Q2 Results

Jazz Pharmaceuticals (JAZZ) reported Q2 sales above estimates and raised its FY26 sales guidance. Analysts have mixed opinions, with some raising price targets. Consider buying JAZZ stock.

Avi Kapoor

PRO
Jazz Pharmaceuticals Raises FY2026 Sales Guidance from $4.250B-$4.500B to $4.600B-$4.750B vs $4.517B Est

Jazz Pharmaceuticals (NASDAQ:JAZZ) raises FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.600 billion-$4.750 billion vs $4.517 billion estimate.

Benzinga Newsdesk

PRO
Jazz Pharmaceuticals Q2 Adj. EPS $5.71 Misses $6.18 Estimate, Sales $1.208B Beat $1.115B Estimate

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $5.71 per share which missed the analyst consensus estimate of $6.18 by 7.61 percent. This is a 169.21 percent increase over losses of $(8.25) per share

Benzinga Newsdesk

PRO
Jazz Pharmaceuticals Affirms FY2026 Sales Guidance of $4.250B-$4.500B vs $4.445B Est

Jazz Pharmaceuticals (NASDAQ:JAZZ) affirms FY2026 sales outlook from $4.250 billion-$4.500 billion to $4.250 billion-$4.500 billion vs $4.445 billion estimate.

Benzinga Newsdesk

PRO
Jazz Pharmaceuticals Q1 Adj. EPS $6.34 Beats $4.57 Estimate, Sales $1.609B Beat $976.563M Estimate

Jazz Pharmaceuticals (NASDAQ:JAZZ) reported quarterly earnings of $6.34 per share which beat the analyst consensus estimate of $4.57 by 38.73 percent. This is a 277.38 percent increase over earnings of $1.68 per share

Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

© 2026 Benzinga | All Rights Reserved